Farallon Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Farallon Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,000	Closed	-$613K	–	98
2026 Q1	$613K	Hold	26,000	–	–	﹤0.01%	108
2025 Q4	$755K	Hold	26,000	–	–	﹤0.01%	90
2025 Q3	$490K	Hold	26,000	–	–	﹤0.01%	92
2025 Q2	$365K	Hold	26,000	–	–	﹤0.01%	100
2025 Q1	$407K	Hold	26,000	–	–	﹤0.01%	97
2024 Q4	$362K	Hold	26,000	–	–	﹤0.01%	104
2024 Q3	$242K	Hold	26,000	–	–	﹤0.01%	130
2024 Q2	$242K	Sell	26,000 -1,754,000	-99%	-$15.9M	﹤0.01%	125
2024 Q1	$17.6M	Buy	+1,780,000	New	+$13.3M	0.07%	78

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Farallon Capital Management's ARQT Position: Q2 2026 in Review

Farallon Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 26,000 shares — an estimated $613K sold.

Farallon Capital Management first reported a position in ARQT in Q1 2024 and held it in 9 quarters. The position peaked at $17.6M in Q1 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Farallon Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Farallon Capital Management sold 26,000 Arcutis Biotherapeutics shares in Q2 2026, an estimated $613K.
Farallon Capital Management first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 9 quarters.
Farallon Capital Management's Arcutis Biotherapeutics position peaked at $17.6M in Q1 2024.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.